Bring Out Your Dead: A Review of the Cost Minimisation Approach in Health Technology Assessment Submissions to the Australian Pharmaceutical Benefits Advisory Committee.

Autor: Tirrell Z; Macquarie University, Macquarie University Centre for the Health Economy, Macquarie Park, NSW, Australia. zachary.tirrell@hdr.mq.edu.au.; Macquarie Business School, Macquarie University, Macquarie Park, Australia. zachary.tirrell@hdr.mq.edu.au.; Australian Institute for Health Innovation, Macquarie University, Macquarie Park, Australia. zachary.tirrell@hdr.mq.edu.au., Norman A; Macquarie University, Macquarie University Centre for the Health Economy, Macquarie Park, NSW, Australia.; Macquarie Business School, Macquarie University, Macquarie Park, Australia.; Australian Institute for Health Innovation, Macquarie University, Macquarie Park, Australia., Hoyle M; Macquarie University, Macquarie University Centre for the Health Economy, Macquarie Park, NSW, Australia.; Macquarie Business School, Macquarie University, Macquarie Park, Australia.; Australian Institute for Health Innovation, Macquarie University, Macquarie Park, Australia., Lybrand S; Macquarie University, Macquarie University Centre for the Health Economy, Macquarie Park, NSW, Australia., Parkinson B; Macquarie University, Macquarie University Centre for the Health Economy, Macquarie Park, NSW, Australia.; Macquarie Business School, Macquarie University, Macquarie Park, Australia.; Australian Institute for Health Innovation, Macquarie University, Macquarie Park, Australia.
Jazyk: angličtina
Zdroj: PharmacoEconomics [Pharmacoeconomics] 2024 Nov; Vol. 42 (11), pp. 1287-1300. Date of Electronic Publication: 2024 Aug 24.
DOI: 10.1007/s40273-024-01420-9
Abstrakt: Objectives: Published literature has levied criticism against the cost-minimisation analysis (CMA) approach to economic evaluation over the past two decades, with multiple papers declaring its 'death'. However, since introducing the requirements for economic evaluations as part of health technology (HTA) decision-making in 1992, the cost-minimisation analysis (CMA) approach has been widely used to inform recommendations about the public subsidy of medicines in Australia. This research aimed to highlight the breadth of use of CMA in Australia and assess the influence of preconditions for the approach on subsidy recommendations METHODS: Relevant information was extracted from Public Summary Documents of Pharmaceutical Benefits Advisory Committee (PBAC) meetings in Australia considering submissions for the subsidy of medicines that included a CMA and were assessed between July 2005 and December 2022. A generalised linear model was used to explore the relationship between whether medicines were recommended and variables that reflected the primary preconditions for using CMA set out in the published PBAC Methodology Guidelines. Other control variables were selected through the Bolasso Method. Subgroup analysis was undertaken which replicated this modelling process.
Results: While the potential for inferior safety or efficacy reduced the likelihood of recommendation (p < 0.01), the effect sizes suggest that the requirements for CMA were not requisite for recommendation.
Conclusion: The Australian practice of CMA does not strictly align with the PBAC Methodology Guidelines and the theoretically appropriate application of CMA. However, within the confines of a deliberative HTA decision-making process that balances values and judgement with available evidence, this may be considered acceptable, particularly if stakeholders consider the current approach delivers sufficient clarity of process and enables patients to access medicines at an affordable cost.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: